On its earnings conference call earlier, United Therapeutics (UTHR) announced a “category killer product” called Tresmi, a “revolutionary proprietary drug device formulation of treprostinil into a soft mist inhaler.” United Therapeutics said Tresmi will reduce the number one side effect of dry powder inhalers, which is coughing, by up to 90%, based on the human studies it has done so far. The company intends to file for its approval in PAH and ILD this year and commercially launch it next year. TheFly notes that shares of MannKind (MNKD), which earns royalties from United Therapeutics’ dry powder inhaler, Tyvaso DPI, are down 39% to $3.38 in morning trading.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- MannKind sinks after United Therapeutics announces soft-mist inhaler
- United Therapeutics reports Q4 EPS $7.70, consensus $7.24
- UTHR Earnings this Week: How Will it Perform?
- United Therapeutics: Buy Rating Backed by De-Risked IPF Phase 3 and Underappreciated PAH Upside Beyond Tyvaso Noise
- United Therapeutics Nears Key Data Milestone With Completed TETON-1 IPF Trial